Alder BioPharmaceuticals Reports Second Quarter 2016 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Alder BioPharmaceuticals Reports Second Quarter 2016 Financial and Operating Results
July 27, 2016 10:36 AM EDT
Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and $45 price target on Alder Biopharm (NASDAQ: ALDR) following Q2 results, recent data showing ALD403's durability and Phase 3 data in the 1st-half of 2017.
Aschoff commented, "Alder ended 2Q16 with cash of $450M, which should be able to support operations into 2H18. On Monday, Alder announced positive top-line 24-week data demonstrating sustained migraine... More
July 27, 2016 8:29 AM EDT
Jefferies analyst Brian Abrahams reiterated a Buy rating and bumped his price target on Alder Biopharm (NASDAQ: ALDR) to $62.00 (from $61.00) as '403 continues to advance.
Abrahams commented, "ALD403 continues to advance on track, and expenses were in line with expectations. Announced... More
July 26, 2016 4:17 PM EDT
Alder BioPharma (NASDAQ: ALDR) reported Q2 EPS of ($0.79), $0.04 worse than the analyst estimate of ($0.75).
For earnings history and earnings-related data on Alder BioPharma (ALDR) click here.
...
More
